An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
← catalyst calendarNCT05494606 · readout ≤ 590 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
785actual
Sites
153
Countries
Argentina, Australia, Canada +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-15 | actual | When the study began enrolling |
| Primary completion | Mar 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Primary outcomes
what the primary-completion date above is the date OFMedian Time to Achieve the First Clinical Response (CR) per Partial Adapted Mayo Score
measured Up to approximately week 156
Percentage of Participants Achieving Clinical Response (CR) per Partial Adapted Mayo Score Among those who Achieved CR at Completion of Upadacitinib Induction (either at Week 8 or at Week 16)
measured Week 52
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed